Communicating with patients and families about investigational EZH2 inhibition

Dr. Morgans asks Dr. Agarwal how he communicates the goals, benefits, and uncertainties of EZH2 inhibition plus enzalutamide to patients and families. Dr. Agarwal describes a structured approach to these nuanced conversations.

He starts with the why: enzalutamide targets the androgen receptor (AR), but cancers can become resistant. EZH2 is part of an epigenetic pathway that helps tumors adapt, so the combination aims to block both the primary driver and a resistance mechanism. He sets expectations honestly: early data are encouraging—citing the 6-month versus 14.3-month progression-free survival difference seen in the dose-expansion data—but the approach remains investigational, and the phase 3 trials are designed to confirm whether the combination is better than standard treatments.

Dr. Agarwal keeps the trial design simple, explaining that some studies compare the combination to physician (or patient) choice while others compare it directly to enzalutamide alone, and that randomization is how the field determines what works. He notes that the control arms include very appropriate therapies, removing the discomfort of offering an unacceptable option. He reviews practical realities: more visits, closer monitoring, and possible dose adjustments. He reassures patients that dose reductions are common and not a sign of failure.

Finally, he places the trial within the full set of treatment options—chemotherapy, PARP inhibitors, and radioligand therapy—and emphasizes shared decision-making that balances optimism with realism. Dr. Morgans adds that the attention patients receive from research teams during clinical trial participation is itself therapeutic.

In the next episode, "Explaining EZH2 mechanism and epigenetic regulation to non-specialists and patients," Dr. Morgans describes how she breaks down epigenetic therapy concepts in clear, accessible language.